A Comparison of Tolerability of 10 Inhalations of Symbicort Turbuhaler 160/4.5 mcg and 10 Inhalations of Terbutaline Turbuhaler 0.4 mg on Top of Symbicort Turbuhaler 160/4.5 mcg 1 Inhalation Bid, Randomized, Double-Blind, Cross Over, Phase III Study in Japanese Adults Asthma Patients

AstraZeneca0 个研究点目标入组 24 人开始时间: 待定

适应症

试验速览

暂无简介。

研究类型: Interventional
干预模型: Treatment, Randomized, Double Blind Crossover Assignment, Pharmacodynamics Study

•Provision of informed consent prior to any study specific procedure
•A minimum of 6 months documented history of asthma according to the JGL2006/GINA2006 definition
•FEV1>70% of predicted normal value pre-bronchodilator

•Having a known or suspected allergy to study therapy (active drugs or additive)
•Having a known clinical history of hypertension, relevant arrhythmias or other heart disease, eg, ischemic heart disease, cardiomyopathy, valvular heart disease, or heart failure
•Having been treated with oral, parenteral or rectal glucocorticoids within 4 weeks, or with depot parenteral glucocorticoids with 3 months
•Respiratory infection significantly affecting the asthma, as judged by the investigator within 4 weeks

Vital signs

blood pressure, pulse rate, body temperature

未报告次要终点

发起方